CSPC Pharmaceutical Group has published the Phase III clinical trial results for its chemically synthesized semaglutide injection (HD1916) in the journal Diabetes, Obesity and Metabolism. The multicenter, randomized study demonstrated that HD1916 achieved an average weight reduction of 13.1% after 44 weeks of treatment in non-diabetic obese Chinese adults. The formulation met pre-specified equivalence criteria when compared head-to-head against Novo Nordisk's biologic semaglutide, with a similar safety profile and good tolerability. The chemically synthesized approach offers distinct manufacturing advantages over traditional biologic fermentation methods, including the elimination of immunogenicity risks, more controllable impurity profiles, and greater potential for quality consistency. CSPC has submitted New Drug Applications to China's NMPA for both type 2 diabetes and overweight/obesity weight management, both of which are currently under review.

Guangzhou DeepSurgery Medical Device Technology Co., Ltd. recently completed a Series B financing round of nearly RMB 100 million, co-led by Med-Fine Capital and China Grand Prosperity, with participation from Chenhui Venture Capital, CS Capital, DIG GROUP, and existing shareholder Wondfo Chuangu. RCCAPITAL acted as the exclusive financial advisor. This marks the company's third financing round in 15 months. Proceeds will support multi-indication clinical trials, registration and approval, and domestic and international market expansion for its flagship FUNZAR microsurgical robot. As the world's first modular general-purpose microsurgical robot, FUNZAR has entered China's National Innovative Medical Device Special Review Program. The company aims to advance microsurgery from standalone microscopes to integrated surgical systems, strengthening its position in sub-micron precision surgery.

In March 2025, Krezen successfully observed recombinant human collagen fibrils resembling natural structures under electron microscopy, shifting its R&D focus from protein yield to structural authenticity. China's recombinant collagen market is projected to reach RMB 66.5 billion by 2027, yet founder Li Yang noted a shortage of high-end products meeting international standards. Animal-derived collagen faces immunogenicity risks, while most recombinant alternatives struggle to replicate natural structures. Krezen aims to overcome these challenges by developing structurally authentic biomaterials for regenerative medicine, addressing industry bottlenecks and enhancing the global competitiveness of Chinese companies.

NOVAST listed on the ChiNext board on October 15, 2026, rather than completing a primary market financing round; therefore, no specific fundraising amount, round, or financial advisor was reported. Founded by Dr. Zhang Guohua, the company specializes in high-barrier sustained- and controlled-release formulations and their global expansion. With 48 FDA approvals, it holds leading U.S. market shares in several products. Early investors included Legend Capital, Danqing Phase II Fund, Xiamen C&D Inc., and the China International Trade in Services Development Fund. IPO proceeds will support R&D, capacity expansion, and internationalization, strengthening its presence in the U.S. prescription drug market. In 2025, revenue reached RMB 895 million and net profit RMB 228 million.

As of August 2026, 442 innovative medical devices have been approved through the "green channel," nearly half in the past three years, a 48% CAGR. Yet accelerated approvals do not guarantee commercial success, given high barriers and clinical costs. VCBeat notes approval is only the start: track selection, continuous iteration, and globalization and volume-based procurement capabilities drive sales past RMB 100 million. Cardiovascular/interventional devices lead with 105 approvals, followed by radiotherapy/oncology and imaging devices, while surgical robots approach an explosion inflection point. Beijing, Shanghai, Jiangsu, Guangdong, and Zhejiang account for ~75.1% of approvals, with Beijing strong in neuromodulation and vascular intervention. The article stresses converting clinical value into sustainable commercial value to pass the post-registration test and complete the leap from innovation to scaled success.

On September 19, 2026, Guangzhou Hipower Pharmaceutical R&D Co., Ltd. announced the close of a RMB 70.06 million Series B+ round, led by Grand Flight, an alternative investment platform of Far East Horizon, with Guangzhou Health Industry Investment, Wanlian Guangsheng, Liwan Guangyao Fund, and Jingxi Investment participating. The proceeds will mainly support iteration of AI-assisted protocol design and enrollment feasibility assessment tools, strengthen real-time data quality control, risk identification, and end-to-end traceability, and codify research methods and evidence requirements into reusable design and quality-control rules. The investment aims to shorten protocol preparation time, reduce the risk of enrollment delays and downstream data rework, and improve schedule control and data reliability in multicenter studies.

On October 19, 2026, Elem Biotechnology completed an angel financing round amounting to tens of millions of RMB. The round was led by HONGHUI CAPITAL, with participation from Xinghua Dingli and Hangzhou Runmiao Fund. Chuanyue Zhouqi served as the financial advisor for this round. Following the completion of this financing, Elem Biotechnology will continue to deepen its strategic layout in high-throughput cell editing services, integration of automated equipment and data production, as well as standardized cell line products. The company aims to provide sustained support to virtual cell enterprises and innovative pharmaceutical companies, covering the entire workflow from "perturbation samples and experimental data to subsequent validation." With the continuous accumulation of high-quality data and off-the-shelf reporter cell assets, Elem Biotechnology seeks to accelerate the practical application of virtual cell technology in drug development.

Zhuhai Trinomab Pharmaceutical Co., Ltd., based in Jinwan District, has officially launched Xinduotuo (ruiteweibai monoclonal antibody injection), the world's first long-acting anti-RSV monoclonal antibody with clinical data demonstrating up to nine months of protection from a single dose. As China's first domestically developed original-research preventive antibody targeting RSV in infants, the product fills a critical gap in the country's pediatric prevention arsenal and marks a significant milestone in China's biotech innovation.

A Jiaxing-based biotech startup, Shengtai Inno, has received approval from China's National Medical Products Administration to begin clinical trials for BCP601 Islet Cell Injection. Developed over six years by Dr. Yang Zijiang and his team, this therapy uses natural pluripotent stem cells to replace damaged insulin-producing cells, aiming to achieve a functional cure for diabetes. As the first domestically developed therapy of its kind in China and only the second globally, BCP601 seeks to offer a transformative, one-time treatment that could significantly reduce the lifetime burden of insulin therapy and its complications. The company emphasizes affordability and breaking the Western monopoly in this field, aligning with China's strategic focus on cell and gene therapy.

Chengdu Easton Bio Pharmaceuticals Co., Ltd. (688513.SH) has obtained a Drug Registration Certificate from the National Medical Products Administration for its ponatinib tablets, a third-generation BCR-ABL tyrosine kinase inhibitor. The approval, issued to the company's wholly-owned subsidiary Chengdu Shuode Pharmaceutical, covers the treatment of adult patients with chronic myeloid leukemia resistant to prior therapies, relapsed or refractory CML, Philadelphia chromosome-positive acute lymphoblastic leukemia, and patients harboring the T315I mutation. The milestone strengthens Easton Bio's hematology-oncology portfolio and expands treatment options for patients with limited therapeutic alternatives.

In 2026, U.S. surgical robotics company Vicarious Surgical filed for bankruptcy and liquidation after prolonged FDA approval delays and limited clinical progress, despite investment from Bill Gates. In contrast, MedBot forecast significant first-half profit growth, signaling a commercial breakthrough for domestic peers. The contrast highlights a shift from technical innovation to hospital adoption, recurring consumables revenue, and cash flow. Despite active domestic financing, surgical robotics requires years of regulatory approval, clinical validation, physician training, and sales development. Approval alone does not guarantee orders, as Longwell Medical's challenges demonstrate. ShuRui expects to break even only in 2029, underscoring the industry's long commercialization cycle. Capital can accelerate R&D but cannot replace the time needed to build physician adoption. Sustainable profitability ultimately depends on a viable business model.

As single-point medical AI tools struggle to enter core clinical workflows, the article argues "AI + hospital" hinges on embedding AI as a decision-support collaborator. Take Tairex's Agent Hospital: its multi-agent ecosystem lets doctors "teach by example" avatars that become assistants. In practice, a respiratory specialist AI avatar instantly flags a contraindication for a hyperthyroidism patient, averting risk. The agents pass on experience, sharpen skills and act as a hub across doctors, patients and departments, cutting friction. After its virtual clinic, Tairex launches a multidisciplinary human-AI consultation feature on October 21, 2026, for earlier, cheaper, higher-quality services. Going forward, multiple agents will collaborate on one operating system. Core point: AI and doctors should collaborate, not replace, lifting care efficiency and quality toward a shared-intelligence future.

In October 2026, DRA, a joint venture between Dennis Lo Yuk-ming's team and KingMed Diagnostics, was officially dissolved, ending an eight-year collaboration backed by RMB 150 million. Established in 2018 with equal 50% stakes, DRA aimed to commercialize high-end non-invasive prenatal testing (NIPT) based on copy number variation sequencing (CNV-seq), leveraging Lo's patents and KingMed's distribution network. Despite favorable market expectations and strong academic backing, the venture failed to commercialize any products and was terminated as no longer necessary. The case highlights the gap between scientific achievements and commercial success, underscoring the challenges of translating academic intellectual property into marketable products and the risks of investing in scientist-led ventures without a viable commercialization pathway.

China's checkup industry handles nearly 600 million visits a year, yet "checkup-only" service and low follow-up rates persist. Amid rising medical insurance pressure and the "Healthy China 2030" policy drive, health management is shifting from treatment-centred to health-centred. China's sub-health market is set to top RMB 1.4 trillion by 2030; with chronic disease management added, proactive health is a trillion-yuan track. Against this backdrop, Topsky is upgrading from a traditional checkup informatisation provider to a proactive health service provider. With lifestyle medicine as its methodology and AI as its foundation, it is extending into hospitals, enterprises, insurance and elderly care to cut medical costs through earlier intervention, build a second growth curve and reshape its commercial value, meeting DRG/DIP reform and insurers' cost-control needs.

On October 12, 2026, Boehringer Ingelheim inaugurated its China R&D Center in Zhangjiang, Shanghai, integrating scientific discovery, early development, and translational research. The center aims to strengthen early clinical development and external innovation. Its Early Medical Team will focus on disease mechanisms, biomarkers, and proof-of-concept studies, with China participating in all pre-PoC projects. The External Innovation Team will seek local opportunities through business development and licensing (BD&L) and venture capital investments. The China team currently participates in over 70% of the company's early-stage clinical studies and all pivotal trials, supporting global first launches and simultaneous drug approvals.

A string of listed pharma companies, including Yuwell Medical, EasyDiagnosis and INTCO Medical, are pouring hundreds of millions of yuan into funds targeting AI and semiconductors for cross-sector gains. The move follows Andon Health's "core healthcare + tech investment" dual-engine model, whose AI bets drove sharp profit growth, proving tech investing a second growth curve. Healthcare firms are thus more cautious on vertical healthcare bets, favouring funds such as Gaorong Changying and SMIC Juyuan. Yuwell Medical itself has repeatedly subscribed to funds targeting AI and semiconductor chips, seeking both returns and supply-chain security for core device components. Healthcare capital is re-selecting GPs and reaching into frontier tech — AI, semiconductors, commercial space — for new value growth beyond the main business.

In 2026, China's brain-computer interface (BCI) sector has seen rapid industrialization and intensifying talent competition. Driven by technological advances and capital inflows, demand for cross-disciplinary professionals in algorithms, hardware, and commercialization has surged. Invasive and non-invasive technologies using optical, electrical, and magnetic approaches have widened talent gaps. Domestic financing reached billions of yuan in H1 2026, prompting companies to expand teams and offer competitive salaries. Annual pay for key implantable BCI positions has reached RMB 1.5 million, while senior neuroscience PhDs can earn over RMB 1 million. Despite an official reference range of RMB 180,000–470,000 from Beijing's human resources authority, million-yuan packages are increasingly common. As the sector shifts from research to commercialization, demand for elite interdisciplinary talent continues to rise, with compensation reflecting technical expertise.

In an interview with VCBeat's "Going Global" column, Puyi Bio Deputy General Manager Wei Zheng discusses how device makers go global. As centralized procurement becomes routine for high-value consumables in China, going global is now a must. Focused on high-end implantable and interventional products, Puyi Bio leans on two core in-house technologies—absorbable polymers and sustained drug release—to win multiple registration certificates at home and abroad. Its distinctive strategy is "patents go global first": overseas patent filings and approvals lead, opening U.S. and European registration pathways and letting the global market feed back into China. As a front-runner in bioabsorbable coronary stents, Puyi Bio cites XinSorb, its first proprietary product, to illustrate a "global first, China later" reverse expansion.

In 2026, Midea Group completed a 100% takeover of Esaote, Europe's largest ultrasound equipment producer, folding it into its Healthcare Division. After Wandong Medical and Carestream, the deal is another heavyweight cross-border move, completing Midea's high-end global positioning. Since taking over Wandong in 2021, Midea has set its imaging strategy, consolidating KUKA and Swisslog via sustained R&D and capital moves, launching an independent Healthcare Division in 2025 as a core group segment. With former GE HealthCare executive Chen Jinlei joining and the deal closed, Midea has built a global sales and qualification network spanning ultrasound, DR, MRI and digital imaging. From loose appliance-adjacent incubation to high-profile industrial M&A, Midea is shaking up the global medical imaging market as a competitor not to be ignored.

In August 2026, China's first commercial-scale dual-chamber lyophilized formulation production line completed equipment installation at WuXi Biologics' Chengdu facility. Initiated by VISEN, manufactured by WuXi Biologics, and equipped by Tofflon, the project was completed in just 10 months, demonstrating strong industry chain collaboration. Designed for VISEN's first commercial product, Weizhengao®, the line integrates liquid filling and lyophilization molding to optimize drug formulation, packaging, and manufacturing. By overcoming patent barriers related to dual-chamber cartridge pens, VISEN has extended innovation beyond drug development to manufacturing and patient experience. The technology enables room-temperature storage and convenient home injection, highlighting the industry's shift toward addressing the entire drug lifecycle, including storage, transportation, and administration, as a new source of competitive advantage.

On October 12, 2026, Boehringer Ingelheim inaugurated its China R&D Center in Zhangjiang, Shanghai, integrating scientific discovery, early development, and translational research. The center aims to strengthen early clinical development and external innovation. Its Early Medical Team will focus on disease mechanisms, biomarkers, and proof-of-concept studies, with China participating in all pre-PoC projects. The External Innovation Team will seek local opportunities through business development and licensing (BD&L) and venture capital investments. The China team currently participates in over 70% of the company's early-stage clinical studies and all pivotal trials, supporting global first launches and simultaneous drug approvals.

Viatris Inc. has announced a $1.65 billion cash acquisition of Pacira BioSciences to expand its non-opioid pain management portfolio with established products like EXPAREL and ZILRETTA. In global regulatory developments, China's Jiangsu Hengrui Pharmaceuticals reported that the European Medicines Agency (EMA) has accepted its marketing authorization application for fluzoparib, a PARP inhibitor for metastatic castration-resistant prostate cancer, highlighting its growing ambitions in European markets.

In the first three quarters of 2026, Medtronic invested approximately $2.7 billion in intensive M&A activities. This included leading a $100 million Series D financing round for China-based Pulnovo Medical. Additionally, Medtronic made strategic investments of approximately $700 million in China's Cornerstone Robotics and Israel's Pi-Cardia; acquired three companies, including CathWorks and Scientia Vascular; and invested in Beluga Medical and CARDIOACC. Although the specific financial advisors were not explicitly mentioned in the text, PwC provided relevant data support. Leveraging its strong cash flow, Medtronic aims to address gaps in cardiology and neuroscience through strategic acquisitions, rapidly acquiring high-growth, near-commercialization innovative technologies to synergize with existing businesses and drive growth.

The recent $7.8 billion deal between Novartis and China’s Abogen Biosciences for the mRNA-encoded T-cell engager ABO2203 marks a pivotal shift in the mRNA landscape—from vaccines to programmable therapeutics. As multinational pharma increasingly prioritizes platform capabilities over single molecules, the spotlight turns to delivery technologies that enable precise, repeatable in vivo expression. Companies like METiS TechBio are emerging as key players by combining AI-driven nanodelivery platforms with modular therapeutic payloads, aiming to validate not just individual candidates like MTS-109—a trispecific mRNA-TCE for autoimmune diseases—but the broader potential of 'in-body drug manufacturing.' With clinical data still early, this wave represents a strategic bet on the future of immune engineering, where success hinges less on what mRNA encodes and more on where it’s delivered.

In late September, two global oncology BD deals worth about $2 billion each highlighted the value of Chinese innovative drugs. MSD is acquiring SciBrunch's preclinical oral KRAS G12D inhibitor SPR2015 for up to $2.13 billion to strengthen its solid tumor pipeline. AstraZeneca is investing $2 billion in Summit Therapeutics to advance combination therapies involving Akeso's ivonescimab and CLDN18.2 ADC, while expanding collaboration on multiple ADCs. Despite similar deal sizes and Chinese origins, the transactions reflect different strategies: MSD is using a preclinical small molecule to fill pipeline gaps, while AstraZeneca is leveraging a mature bispecific antibody to explore combination therapies. The deals highlight diverse asset stages, deal structures, and strategic approaches in global oncology BD, as well as the growing global value of Chinese biopharmaceutical innovation.

On September 28, 2026, Shanghai SciBrunch and MSD announced a global exclusive licensing agreement for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor. Under the agreement, SciBrunch grants MSD exclusive worldwide rights to develop, manufacture, and commercialize SPR2015. The deal includes a $400 million upfront payment and milestone payments, with a potential total value of up to $2.13 billion. SPR2015 is a potent and selective molecular glue inhibitor targeting KRAS G12D, the most common KRAS mutation in human tumors. Preclinical studies showed significant antitumor activity across multiple models while maintaining favorable selectivity for wild-type KRAS. The collaboration validates SciBrunch’s R&D capabilities in RAS-targeted therapies and strengthens MSD’s precision medicine pipeline, with potential applications in pancreatic, colorectal, and lung cancers.

Dr. Friedemann Janus, Senior Vice President of Bayer's Pharmaceuticals Division, said China's innovative drugs are embedding deeply into the global system, with about a third of drugs in development originating from China. Multinational pharma's China strategy has shifted from license-in of mature pipeline assets to early engagement with biotech teams to grasp their innovation logic. Bayer, which sees China as a key source of high-quality innovation, has built a network linking startups with global capital and R&D experts via Co.Lab sites in Shanghai and Beijing, a venture capital alliance, and global roadshows during 2024–2025. Janus believes China's pharma industry has moved past "Me-too" and "Fast-Follow" toward "Best-in-Class." The core issue now is how multinational pharma can embed even earlier in China's innovation ecosystem and drive local innovation into global R&D, business development, and commercialization — a fundamental elevation of China's global pharma position.

China’s Center for Drug Evaluation (CDE) has nominated two MASH drug candidates for breakthrough therapy designation: Zhongsheng Pharmaceutical’s ZSP1601 tablets and GSK’s injectable Efimosfermin alfa. ZSP1601, a first-in-class pan-phosphodiesterase (PDE) inhibitor, has entered Phase III trials after showing significant pathological improvement in Phase IIb. At 48 weeks, response rates were 64.9% (100 mg) and 57.6% (50 mg), versus 32.5% for placebo. The drug demonstrated anti-fibrotic effects, reduced liver fat, and improved liver enzymes, with a favorable safety profile. Efimosfermin alfa, a long-acting FGF21 analog administered monthly by subcutaneous injection, is designed to reduce liver fat, improve inflammation, and reverse fibrosis. GSK acquired rights to the drug for up to USD 2 billion and has registered the Phase III ZENITH-2 trial in China following positive Phase II results showing significant histological response in patients with F2/F3 MASH.

On September 22, Suzhou BoomRay announced an exclusive global licensing agreement with Novartis for one of its preclinical radioligand therapy (RLT) assets. BoomRay is eligible to receive up to USD 900 million (approximately RMB 6 billion), including upfront and milestone payments, plus sales royalties. This marks Novartis’s second licensing of an early-stage RLT asset from China this year, following its January acquisition of assets from Hunan PepLib. Despite strong RLT sales, including over USD 1.9 billion in 2025 revenue from Pluvicto, Novartis continues to seek external collaborations to expand its next-generation pipeline targeting novel antigens, ligands, and radionuclides. Founded in 2018, BoomRay has developed an RLT platform covering multiple targets. The deal highlights the global licensing potential of Chinese biotech RLT assets and the growing focus of multinational pharmaceutical companies on early-stage RLT opportunities.

At CCOS 2026, Zhang Jian, vice president of Alcon China, said innovation value must be reflected in responding to real clinical needs and benefiting patients. As China's ophthalmic demands shift from basic "blindness treatment" toward high-definition, personalized, all-scenario visual quality, competition now extends to clinical application capability, professional education, and local innovation. Alcon is redefining its value in China by deepening the integration of global innovation with local clinical practice. It showcased products including the Clareon intraocular lens, the Constellation system, and the ARGOS biometer, and is advancing the rollout of Unity VCS — marking a shift from single devices to systematic clinical solutions, and aiming to complete innovation's "last mile" through continuous clinical validation to genuinely improve patient outcomes.